VLS Valneva SE

Shareholding declaration Valneva SE - January 2025

Shareholding declaration Valneva SE - January 2025

VALNEVA

Declaration of shares and voting rights

January 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: February 6, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 



162,521,524



 ordinary shares with a par value of €0.15 each











178,407,257  



 



Double voting rights granted on 2282 ordinary shares



 
 



Between January 9 & 24, 2025
178,282,935

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Shareholding declaration Valneva SE - January 2025

Shareholding declaration Valneva SE - January 2025 VALNEVA Declaration of shares and voting rights January 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: February 6, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized To...

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Valneva: Ixchiq approved in the UK

Valneva’s Chikungunya vaccine, Ixchiq, has received marketing authorization from the MHRA and is set to enter the UK market for individuals aged 18 and older. While this approval was anticipated, the UK’s traveller market will now complement the EU4, where the vaccine has been approved since last J

 PRESS RELEASE

Valneva Receives Marketing Authorization in the UK for the World’s Fir...

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® Saint Herblain (France), February 5, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vac...

 PRESS RELEASE

Valneva reçoit une autorisation de mise sur le marché au Royaume-Uni p...

Valneva reçoit une autorisation de mise sur le marché au Royaume-Uni pour le premier vaccin au monde contre le chikungunya, IXCHIQ® Saint Herblain (France), le 5 février 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’autorité de santé britannique Medicines and Healthcare products Regulatory Agency (MHRA) a accordé une autorisation de mise sur le marché au Royaume-Uni à IXCHIQ®, le premier et le seul vaccin au monde contre le chikungunya. Le vaccin à dose unique de Valneva est indiqué pour une immunisation active pour la prévent...

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Valneva: Renewed USD32.8m DoD contract for Ixiaro

Valneva announced the signing of a new USD32.8m contract with the DoD for the supply of Ixiaro, with the possibility to purchase additional doses during the coming 12 months. While largely expected considering the long-term relationship the company has with the DoD, we nonetheless welcome this news

ResearchPool Subscriptions

Get the most out of your insights

Get in touch